Foundation congratulates Baxter, Kamada on agreement to distribute augmentation therapy; hopes for closer relationship with community
MIAMI – The Alpha-1 Foundation today congratulated Baxter International and Kamada Ltd. on their new agreement for the distribution and manufacture of Kamada’s intravenous alpha-1 antitrypsin product Glassia for treatment of Alpha-1 Antitrypsin Deficiency.
Baxter will have exclusive rights to Glassia in the United States, Australia, New Zealand and Canada. Kamada, an Israeli biopharmaceutical company, developed Glassia, which was approved in July by the US Food and Drug Administration.
“We are pleased that Baxter, with its extensive experience in the Alpha-1 market, has contracted for the distribution,” said Foundation President & CEO John Walsh. “We are hopeful that this agreement will provide an opportunity for much closer cooperation with the Alpha-1 community. We also hope that this agreement will assist Kamada in accelerating the development of aerosolized therapy for Alpha-1.”
Walsh added that the Foundation has been closely involved with supporting the development of Alpha-1 augmentation therapies, clinical trial design and recruitment, with its clinical leadership and individuals in the Foundation’s Alpha-1 Research RegistryDownload the full press release on our WEBSITE.
